Ozempic, Wegovy maker calls out Hims & Hers Super Bowl ad: ‘Check before you inject’
Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and Drug Administration.
Novo Nordisk: 2024 Earnings Review
Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.
Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.
Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Zacks Investment Research on MSN8d
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?
Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...
WUSF Public Media9d
About half of Americans approve of using weight-loss drugs to treat obesity, a poll finds
The AP-NORC survey shows about half of U.S. adults believe it is a good thing for adults to use Ozempic, Wegovy and similar ...
Fact-Checking Health Claims in Kennedy’s 2nd Day of Confirmation Hearings
Robert F. Kennedy Jr., the nominee to lead the Department of Health and Human Services, made disputed claims before the ...
The Mirror14d
Everything you need to know about weight loss jabs such as Wegovy as chemists demand clampdown
It was dubbed the "King Kong" of weight loss drugs by US expert Dr Julio Rosenstock after its effect size emerged , compared to the "gorilla" of Wegovy. The two biggest selling GLP-1 drugs are ...